BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years

BRAINSTORM CELL THERAPEUTICS INC.

9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.
Median survival in small cohort was 6.8 years; only death was elective euthanasia.
Company says data strengthens rationale for Phase 3b trial of NurOwn in ALS under FDA SPA.
CEO and CMO highlighted clinically meaningful observation in press release.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.